Interaction of cytosine arabinoside and lovastatin in human leukemia cells

Leukemia Research

Volumn 25, Issue 8, 2001, Pages 651-660

  Holstein, Sarah A ^a   Hohl, Raymond J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; Cytosine arabinoside; HMG CoA reductase; MAPK; RAS

Indexed keywords

CYTARABINE; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

APOPTOSIS; ARTICLE; CELL COUNT; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; DRUG INTERACTION; DRUG RESISTANCE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; CYTARABINE; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; K562 CELLS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LOVASTATIN; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; RAS PROTEINS;

EID: 0035020378     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00162-4     Document Type: Article

References (48)

1. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study
2. Varying intensity of postremission therapy in acute myeloid leukemia
3. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group
4. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
5. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia
6. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
7. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, campthothecin, and other cytotoxic anticancer drugs: a cautionary note
8. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine
9. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
10. Protein prenylation: genes, enzymes, and functions
11. ras oncogenes in human cancer: a review
12. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
13. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells
14. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N, N′-bis(2-chloroethyl)-N-nitrosurea and β-interferon on human glioma cells
15. Potentiated antitumor effects of cisplatin and lovastatin against MmB16 melanoma in mice
16. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
17. Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells
18. Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts
19. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene
20. Protein measurement with the Folin phenol reagent
21. Differential effects of monoterpenes and lovastatin on RAS processing
22. Monoclonal antibody highly sensitive for the detection of ras p21 in immunoblotting analysis
23. Criteria for analyzing interactions between biologically active agents
24. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
25. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
26. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl
27. 1-β-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells
28. Terminal erythroid differentiation in the K-562 cell line by 1-β-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease
29. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
30. Lovastatin induces growth inhibition and apoptosis in human glioma cells
31. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach
32. S induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D-arabinofuranosylcytosine-mediated differentiation and apoptosis
33. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
34. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways
35. Evidence for involvement of mitogen-activated protein kinase rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling
36. Ras oncogene-induced sensitization to 1-β-D-arabinofuranosylcytosine
37. Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene
38. All ras proteins are polyisoprenylated but only some are palmitoylated
39. Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21
40. 1-β-D-Arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidyltransferase
41. The roles of signaling by the p42/p44 mitogen activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity
42. Modulation of 1-[β-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C
43. Ara-C: cellular and molecular pharmacology
44. Tumor resistance to oxidative stress: association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation
45. Superoxide generation in v-Ha-ras transduced human keratinocyte HaCaT cells
46. Pharmacologically directed ara-C therapy for refractory leukemia
47. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma - phase I/II studies and pharmacokinetics
48. Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells